CD56+ AML is strongly associated with AML1/ETO rearrangement and CNS involvement in childhood AML

被引：0
|
作者：
Lee, Hye Ryun [1 ]
Lee, Dong Soon [1 ]
Kim, Inho [2 ]
Yoon, Sung-Soo [2 ]
Park, Seonyang [2 ]
Kim, Young Kook [2 ]
Kang, Hyoung Jin [3 ]
Shin, Hee Young [3 ]
Ahn, Hyo Seop [3 ]
Kim, Hyun Kyung [1 ]
Park, Myoung Hee [1 ]
Cho, Han Ik [1 ]
机构：
[1] Seoul Natl Univ, Coll Med, Dept Lab Med, Seoul, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[3] Seoul Natl Univ, Coll Med, Dept Pediat, Seoul, South Korea
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.4272.4272
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4272
引用
收藏
页码：136B / 136B
页数：1
相关论文
共 50 条
  • [21] Proteomics of AML1/ETO target proteins: AML1-ETO targets a C/EBP-NM23 pathway
    Singh S.M.
    Trivedi A.K.
    Lochab S.
    Christopeit M.
    Hiddemann W.
    Behre G.
    Clinical Proteomics, 2010, 6 (3) : 83 - 91
  • [22] Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation
    V N Thiel
    B D Giaimo
    P Schwarz
    K Soller
    V Vas
    M Bartkuhn
    T J Blätte
    K Döhner
    L Bullinger
    T Borggrefe
    H Geiger
    F Oswald
    Leukemia, 2017, 31 : 2491 - 2502
  • [23] Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation
    Thiel, V. N.
    Giaimo, B. D.
    Schwarz, P.
    Soller, K.
    Vas, V.
    Bartkuhn, M.
    Blaette, T. J.
    Doehner, K.
    Bullinger, L.
    Borggrefe, T.
    Geiger, H.
    Oswald, F.
    LEUKEMIA, 2017, 31 (11) : 2491 - 2502
  • [24] EXPRESSION OF AML1 AND ETO TRANSCRIPTS IN HEMATOPOIETIC-CELLS
    ERA, T
    ASOU, N
    YAMAGUCHI, K
    YAMASAKI, H
    KAMADA, N
    NISHIKAWA, S
    TAKATSUKI, K
    LEUKEMIA, 1995, 9 : S26 - S28
  • [25] Dominant negative effects of the AML1/ETO fusion oncoprotein
    Fenske, TS
    Pengue, G
    Graubert, TA
    CELL CYCLE, 2005, 4 (01) : 33 - 36
  • [26] Disturbed differentiation of AML1/ETO transduced human CD34+progenitors.
    Baesecke, J
    Baum, C
    Pfahlert, O
    Brittinger, G
    Woermann, B
    Griesinger, F
    BLOOD, 2000, 96 (11) : 214A - 214A
  • [27] A retrospective molecular study of the frequency of AML1/ETO, CBFB/MYH11, PML/RARA, and rearrangement of MLL in childhood de novo AML and comparison with survival.
    Behm, FG
    Shurtleff, SA
    Raimondi, SC
    Ribeiro, RC
    Krance, R
    Jayawardene, DA
    Head, DR
    Mirro, J
    Srivastava, DK
    Downing, JR
    BLOOD, 1997, 90 (10) : 275 - 275
  • [28] THE DIFFERENCES IN PROGNOSTIC OUTCOME BETWEEN AML1/ETO AND CBFβ/MYH11 POSITIVE AML PATIENTS
    Markova, J.
    Michkova, P.
    Maaloufova, J. Soukupova
    Soukup, P.
    Cetkovsky, P.
    Schwarz, J.
    HAEMATOLOGICA, 2012, 97 : 273 - 274
  • [29] PIG 7, TRANSACTIVATED BY AML1, PROMOTES APOPTOSIS OF LEUKEMIA CELLS WITH AML1-ETO FUSION GENE
    Wang, J.
    Liu, J.
    Xing, H.
    Wang, L.
    Wang, D.
    Rao, Q.
    Wang, M.
    EXPERIMENTAL HEMATOLOGY, 2010, 38 (09) : S25 - S25
  • [30] The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B
    Frank, R
    Zhang, J
    Uchida, H
    Meyers, S
    Hiebert, SW
    Nimer, SD
    ONCOGENE, 1995, 11 (12) : 2667 - 2674
12345